Search Site

Trends banner

DAE to acquire 17 aircraft for $1 bn

This portfolio comprises 100 percent next-generation aircraft

DP World posts record $20bn revenue

The adjusted EBITDA rose by 6.7% to $5.5bn in 2024.

Meraas awards $544m contract

It has been awarded for construction of Design Quarter at d3

Salik 2024 net profit before taxes $348m

The toll operator's revenue increased by 6% to $626 million.

ADNIC okays 45% dividend for 2024

The company achieved its highest ever revenue and net profit.

Glaxo buys Bellus for US$2bn

A Bellus treatment under clinical development, Camlipixant, is expected to receive regulatory approvals and launch in 2026. (AFP)
  • GSK has agreed to buy Quebec-based biopharmaceutical Bellus Health Inc. for $14.75 per share, the British drugmaker said in a statement.
  • Chronic cough is defined as a persistent cough that lasts more than eight weeks and affects an estimated 28 million people worldwide.

LONDON, UK – British drugmaker GlaxoSmithKline on Tuesday announced the purchase of Canadian chronic cough treatment specialist Bellus for US$2 billion.

It comes after GSK, led by chief executive Emma Walmsley, demerged its consumer healthcare unit Haleon last year, leaving the group to focus on drugs.

GSK has agreed to buy Quebec-based biopharmaceutical Bellus Health Inc. for $14.75 per share, it said in a statement.

Chronic cough, defined as a persistent cough that lasts more than eight weeks, affects an estimated 28 million people worldwide.

While there are no approved medicines in the European Union or United States, a Bellus treatment under clinical development, Camlipixant, is expected to receive regulatory approvals and launch in 2026.

“Patients suffering from severe forms of refractory chronic cough can experience over 900 coughs daily, resulting in quality-of-life issues,” GSK’s chief commercial officer Luke Miels said in the statement.

“Camlipixant… has the potential to be a best-in-class treatment with significant sales potential,” he added.